Thursday, April 18, 2024

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

Most American Parents Rejecting COVID Vaccine for Young Children

mother walking with daughter

Despite the recommendation by the U.S. Centers for Disease Control and Prevention (CDC) that young children between the ages of six months and four years get vaccinated for COVID-19, only four to five percent of children in this age group have received the controversial mRNA COVID vaccines distributed by Pfizer/BioNTech and Moderna for administration to […]

Herpes Zoster Reactivated Following mRNA COVID Shots, Studies Show

herpes zoster rash

Concerns about the adverse effects of mRNA COVID-19 shots continue to grow a year and a half after they began to be distributed under an Emergency Use Authorization (EUA) granted to Pfizer/BioNTech and Moderna by the U.S. Food and Drug Administration (FDA). Cases of herpes zoster (HZ) following messenger RNA (mRNA) COVID shots have been […]

Nuvaxovid Offered as Alternative to mRNA Shots

Nuvaxovid

For a virus (SARS-CoV-2) that many scientists and public health officials have maintained originated in a bat and accidently crossed over into humans, leading to the COVID-19 pandemic, it is odd that there does not appear to be much concern about producing vaccines that use genetic material from animals. You would think that this would […]

VAERS Data Reveal Serious Adverse Event Reports in Babies After mRNA COVID Shots

baby and vaccine

On June 15, 2022, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) advised the FDA to grant an Emergency Use Authorization (EUA) for Moderna/NIAID and Pfizer/BioNTech’s mRNA COVID-19 biologics be given to infants and children under age five and as young as six months old. With […]

FDA Grants EUA for Novavax’s COVID Vaccine

Nuvaxovid

Opinion | On July 13, 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Novavax to distribute its experimental two-dose NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine for use by adults. The decision was expected, given the favorable recommendation by the FDA’s Vaccines and Related Biological Products Advisory […]

Search in Site

To search in site, type your keyword and hit enter

Search